Trials / Completed
CompletedNCT04333134
A Trial of SHR3162 in Healthy Caucasian Volunteers
A Phase 1, Open-Label, Two-Center Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of fluzoparib in healthy Caucasian and Chinese subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR3162 | Fluzoparib, also known as SHR3162, is an inhibitor of human PARP |
Timeline
- Start date
- 2020-04-17
- Primary completion
- 2020-05-15
- Completion
- 2020-06-30
- First posted
- 2020-04-03
- Last updated
- 2022-07-14
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04333134. Inclusion in this directory is not an endorsement.